A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats

Journal of Pharmacological Sciences

Volumn 106, Issue 1, 2008, Pages 144-151

  Kametaka, Sokichi ^a   Kasahara, Takafumi ^a   Ueo, Mayumi ^a   Takenaka, Mariko ^a   Saito, Maki ^a   Sakamoto, Kenji ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Cataract; Diabetes; Imaging; Lens; Streptozotocin

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ALDOSE REDUCTASE INHIBITOR; DRINKING WATER; GLUCOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAMERA; CATARACT; CONTROLLED STUDY; DIGITAL IMAGING; EVALUATION; HYPERGLYCEMIA; IMAGE ANALYSIS; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SCORING SYSTEM; STREPTOZOCIN DIABETES; WISTAR RAT;

EID: 38549140999     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071500     Document Type: Article

References (24)

1. Brian G, Taylor H. Cataract blindness - challenges for the 21st century. Bull World Health Organ. 2001;79:249-256.
2. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet. 1976;2:1009-1012.
3. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology. 1985;92:1191-1196.
4. Jahn CE, Janke M, Winowski H, von Bergmann K, Leiss O, Hockwin O. Identification of metabolic risk factors for posterior subcapsular cataract. Ophthalmic Res. 1986;18:112-116.
5. Brown NP, Bron AJ. Aetiological classification of cataract: Ocular toxic, nutritional and physical factors, and senile cataract. In: Brown NP, Bron AJ, editors. Lens disorders a clinical manual of cataract diagnosis. Oxford: Butterwoth-Heinemann; 1996. p. 90-211.
6. Swamy-Mruthinti S, Shaw SM, Zhao HR, Green K, Abraham EC. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res. 1999;8:423-429.
7. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res. 2002;74:337-347.
8. Hockwin O, Dragomirescu V, Laser H, Wegener A, Eckerskorn U. Measureing lens tency by Scheimpflug photography of the anterior eye segment- principle, instrumentation, and application to clinical and experimental ophthalmology. J Cutaneous Ocular Toxicol. 1987;6:251-271.
9. Kojima M, Wegener A, Hockwin O. Imaging charasteristics of three cameras using the Scheimpflug principle. Ophthalmic Res. 1990;22 Suppl 1:29-35.
10. Masters BR. Three-dimensional microscopic tomographic imaging of the cataract in a human lens in vivo. Optic express. 1998;3:332-338.
11. Berliner ML. Biomicroscopy of the eye: slit lamp microscopy of the living eye. Vol II. New York: Harper & Bros; 1949. p. 1115.
12. Schmitt C, Schmidt J, Hockwin O. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin. Lens Eye Toxic Res. 1990;7:631-642.
13. Kashima K, Trus BL, Unser M, Edwards PA, Datiles MB. Aging studies on normal lens using the slit-lamp camera. Invest Ophthalmol Vis Sci. 1992;34:263-269.
14. Hegde KR, Henein MG, Varma SD. Establishment of the mouse as a model animal for the study of diabetic cataracts. Ophthalmic Res. 2003;35:12-18.
15. Tkachov SI, Lautenschlager C, Ehrich D, Struck HG. Changes in the lens epithelium with respect to cataractogenesis-light microscopic and Scheimpflug densitometric analysis of the cataractous and the clear lens of diabetics and non-diabetics. Graefes Arch Clin Exp Ophthalmol. 2006;244:596-602.
16. Chylack LT Jr, Leske MC, Sperduto R, Khu P, McCarthy D. Lens opacities classification system. Arch Ophthalmol. 1988;106:330-334.
17. Leske MC, Chylack LT Jr, Sperduto R, Khu P, Wu SY, McCarthy D. Evaluation of a lens opacities classification system. Arch Ophthalmol. 1988;106:327-329.
18. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, et al. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism. 1991;40:77-87.
19. Suryanarayana P, Krishnaswamy K, Reddy GB. Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis. 2003;9:223-230.
20. Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn J Pharmacol. 1997;73:133-144.
21. Datiles MB 3rd, Fukui H. Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil. Curr Eye Res. 1989;8:233-237.
22. Banditelli S, Boldrini E, Vilardo PG, Cecconi I, Cappiello M, Dal Monte M, et al. A new approach against sugar cataract through aldose reductase inhibitors. Exp Eye Res. 1999;69:533-538.
23. Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical production. Exp Eye Res. 1999;68:457-464.
24. Kador PF, Lee JW, Fujisawa S, Blessing K, Lou MF. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. J Ocul Pharmacol Ther. 2000;16:149-160.